Chewy (CHWY) Meets Q2 Earnings Estimates

Chewy (CHWY) reported Q3 2025 earnings of $0.33 per share, meeting the Zacks Consensus Estimate, and revenues of $3.1 billion, exceeding expectations by 0.71% and growing from $2.86 billion year-over-year. Despite CHWY's 25.7% year-to-date stock gain, Zacks maintains a #4 (Sell) Rank due to unfavorable estimate revisions, suggesting potential near-term underperformance, with future price action contingent on management's commentary.

Analysis

Chewy, Inc. (CHWY) reported solid operational results for the quarter ended July 2025, with revenues of $3.1 billion representing an 8.4% year-over-year increase and a 0.71% beat against the Zacks Consensus Estimate. This marks the fourth consecutive quarter of topping revenue forecasts. Earnings per share came in at $0.33, in line with consensus and demonstrating significant growth from $0.24 in the prior-year period. Despite this strong performance and a 25.7% year-to-date stock appreciation that outpaces the S&P 500, a critical disconnect exists with forward-looking analyst sentiment. The stock carries a Zacks Rank #4 (Sell), attributed to an unfavorable trend in earnings estimate revisions leading up to the report, signaling potential for near-term market underperformance. This company-specific caution contrasts with the positive outlook for its Internet - Commerce industry, which ranks in the top 34% of Zacks industries, and with the struggles of competitor PetMed (PETS), which is forecasting a 13.6% revenue decline. The sustainability of Chewy's rally is therefore contingent on management's forward guidance from the earnings call, which will be pivotal in reconciling the firm's historical outperformance with the current cautious analyst rating.

Key Decisions for Investors

• Investors should scrutinize management's forward guidance on the upcoming earnings call, as it will be the key catalyst to either validate the stock's recent rally or confirm the bearish sentiment reflected in the pre-earnings estimate revisions.
• Consider that Chewy's consistent revenue growth and market outperformance, especially when contrasted with the expected decline at peer PetMed, may indicate market share gains, but weigh this against the near-term risk highlighted by the Zacks #4 (Sell) rating.
• Given the conflicting signals of strong recent results versus a negative analyst rating, it may be prudent to hold existing positions but exercise caution on initiating new ones until the market digests management's full outlook and subsequent analyst estimate revisions.